Clinical Trial Detail

NCT ID NCT01835184
Title Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

Advanced Solid Tumor

melanoma

Therapies

Cabozantinib + Vemurafenib

Age Groups: adult senior

Additional content available in CKB BOOST